Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Demetrios IoannidesN AntonakopoulosS GeorgiouV ChasapiI KatsantonisA DrososDimitrios RigopoulosC AntoniouG AnastasiadisIoannis D BassukasD IoannidouA ProtopapaO NeofotistouK KrasagakisP AronisM PapageorgiouE LazaridouA PatsatsiI LefakiA V Roussaki-SchulzeF SatraZ AnagnostopoulosM PapakonstantisPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)
These interim results indicate that through 24 weeks, apremilast improved quality of life and reduced disease severity in biologic-naive patients with moderate plaque psoriasis, while demonstrating safety consistent with the known safety profile.